Glaukos stock (US3773221029): Director sale signals confidence near 52-week highs

A Glaukos director sold 5,000 shares on May 11 for $675,000 as the medical device maker trades near its 52-week peak, with analyst price targets clustered around $140.

Glaukos director Gilbert H. Kliman sold 5,000 shares of the company on May 11, 2026, for an estimated $675,000, or $135.00 per share, according to QuiverQuant as of May 14, 2026. The transaction occurs as Glaukos trades near its 52-week high of $146.75, reflecting sustained investor interest in the medical device sector.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Glaukos Corp
• Sector/industry: Medical Devices
• Headquarters/country: United States
• Core markets: Ophthalmology, glaucoma treatment
• Home exchange/listing venue: NYSE (GKOS)
• Trading currency: USD
• Market cap: Approximately $8.01 billion

Glaukos: core business model

Glaukos is a medical device company focused on ophthalmology, particularly the treatment of glaucoma and other eye conditions. The company develops and commercializes minimally invasive glaucoma surgery (MIGS) devices and related solutions. As a publicly traded entity on the New York Stock Exchange, Glaukos serves the US healthcare market and international markets, positioning itself in the broader medical device sector that has shown resilience and growth in recent years.

Analyst sentiment and price targets

Wall Street analysts have maintained a constructive view on Glaukos. According to QuiverQuant as of May 14, 2026, three firms have issued buy ratings on the stock with no sell ratings. Recent price targets from major institutions include $141.00 from BTIG, $140.00 from Citigroup and JPMorgan, $138.00 from Wells Fargo, and $136.00 from Needham, with a median target of $141.00 across nine analysts surveyed in the past six months. These targets suggest analyst confidence in the company's near-term trajectory, though they remain modest relative to the stock's current trading levels.

Insider activity and market context

Director share sales can reflect various motivations, from portfolio rebalancing to tax planning, and do not necessarily signal concern about company fundamentals. Kliman's sale at $135.00 per share, while below the 52-week high, still represents a substantial valuation for the company. The transaction underscores ongoing activity among company insiders as Glaukos maintains its position as a significant player in the medical device space, where innovation in minimally invasive treatments continues to drive market demand.

Conclusion

Glaukos remains a key player in the medical device sector, with analyst support and strong stock performance near 52-week highs. The recent director sale reflects normal insider activity in a company trading at elevated valuations. For US investors tracking the medical device space, Glaukos represents a significant market participant, though individual investment decisions should account for broader market conditions and personal risk tolerance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.